BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sakurai H, Ishikawa H, Okumura T. Proton beam therapy in Japan: current and future status. Jpn J Clin Oncol 2016;46:885-92. [PMID: 27534798 DOI: 10.1093/jjco/hyw102] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Kim E, Jang WI, Kim MS, Paik EK, Kim HJ, Yoo HJ, Yang K, Cho CK. Clinical utilization of radiation therapy in Korea, 2016. J Radiat Res 2020;61:249-56. [PMID: 31913473 DOI: 10.1093/jrr/rrz095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kim KS, Wu HG. Who Will Benefit from Charged-Particle Therapy? Cancer Res Treat 2021;53:621-34. [PMID: 34176253 DOI: 10.4143/crt.2021.299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Shimazu Y, Otsuki R, Murakami M, Konishi A, Kan K, Seto I, Yamaguchi H, Tsubokura M, Hattori H. Age as a decisive factor in general anaesthesia use in paediatric proton beam therapy. Sci Rep 2020;10:15096. [PMID: 32934278 DOI: 10.1038/s41598-020-72223-z] [Reference Citation Analysis]
4 Hoshina RM, Matsuura T, Umegaki K, Shimizu S. A Literature Review of Proton Beam Therapy for Prostate Cancer in Japan. J Clin Med 2019;8:E48. [PMID: 30621278 DOI: 10.3390/jcm8010048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Tian X, Liu K, Hou Y, Cheng J, Zhang J. The evolution of proton beam therapy: Current and future status. Mol Clin Oncol 2018;8:15-21. [PMID: 29399346 DOI: 10.3892/mco.2017.1499] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
6 Takahashi H, Sekino Y, Mori K, Okumura T, Nasu K, Fukuda K, Masuoka S, Iizumi T, Hasegawa N, Sakurai H, Minami M. Indicator for local recurrence of hepatocellular carcinoma after proton beam therapy: analysis of attenuation difference between the irradiated tumor and liver parenchyma on contrast enhancement CT. Br J Radiol 2020;93:20190375. [PMID: 31670572 DOI: 10.1259/bjr.20190375] [Reference Citation Analysis]
7 Yu JI, Yoo GS, Cho S, Jung SH, Han Y, Park S, Lee B, Kang W, Sinn DH, Paik YH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park HC. Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma. Radiat Oncol J. 2018;36:25-34. [PMID: 29580046 DOI: 10.3857/roj.2017.00409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
8 Takahashi H, Mori K, Sekino Y, Okumura T, Hiyama T, Fukuda K, Hasegawa N, Sakai M, Kikuchi S, Takei Y, Iizumi T, Sakurai H, Minami M. Angiographic Findings in Patients with Hepatocellular Carcinoma Previously Treated Using Proton Beam Therapy. J Oncol 2019;2019:3580379. [PMID: 31354819 DOI: 10.1155/2019/3580379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Li P, Wang J, Axier A, Zhou K, Yun J, Wang H, Zhang T, Li S. Proton therapy for craniopharyngioma in adults: a protocol for systematic review and meta-analysis. BMJ Open 2021;11:e046043. [PMID: 34078637 DOI: 10.1136/bmjopen-2020-046043] [Reference Citation Analysis]
10 Nishioka K, Prayongrat A, Ono K, Onodera S, Hashimoto T, Katoh N, Inoue T, Kinoshita R, Yasuda K, Mori T, Onimaru R, Shirato H, Shimizu S. Prospective study to evaluate the safety of the world-first spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy system. J Radiat Res 2018;59:i63-71. [PMID: 29309691 DOI: 10.1093/jrr/rrx083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ono T, Wada H, Ishikawa H, Tamamura H, Tokumaru S. Clinical Results of Proton Beam Therapy for Esophageal Cancer: Multicenter Retrospective Study in Japan. Cancers (Basel) 2019;11:E993. [PMID: 31315281 DOI: 10.3390/cancers11070993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
12 Matsuno Y, Hyodo M, Fujimori H, Shimizu A, Yoshioka KI. Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules. Cancers (Basel). 2018;10:pii: E364. [PMID: 30274183 DOI: 10.3390/cancers10100364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
13 Miyazaki T, Sohda M, Sakai M, Kumakura Y, Yoshida T, Kuriyama K, Yokobori T, Miyazaki M, Hirato J, Okumura T, Ishikawa H, Sakurai H, Kuwano H. Multimodality Therapy Including Proton Beam Therapy for AFP Producing Esophageal Cancer with Multiple Liver Metastases. Intern Med 2018;57:2333-9. [PMID: 29607947 DOI: 10.2169/internalmedicine.0270-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yoshida M, Ogino H, Iwata H, Hattori Y, Hashimoto S, Nakajima K, Sasaki S, Hara M, Sekido Y, Mizoe JE, Shibamoto Y. Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma. Oncol Lett 2019;17:3026-34. [PMID: 30854081 DOI: 10.3892/ol.2019.9922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Eekers DBP, Roelofs E, Cubillos-Mesías M, Niël C, Smeenk RJ, Hoeben A, Minken AWH, Granzier M, Janssens GO, Kaanders JHAM, Lambin P, Troost EGC. Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric in silico ROCOCO trial. Acta Oncol 2019;58:57-65. [PMID: 30474448 DOI: 10.1080/0284186X.2018.1529424] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
16 Iizumi T, Shimizu S, Numajiri H, Takei H, Yamada N, Mizumoto M, Ishikawa H, Okumura T, Sakurai H. Large Malignant Fibrous Histiocytoma Treated with Hypofractionated Proton Beam Therapy and Local Hyperthermia. Int J Part Ther 2019;6:35-41. [PMID: 31773047 DOI: 10.14338/IJPT-18-00046.1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Journy N, Indelicato DJ, Withrow DR, Akimoto T, Alapetite C, Araya M, Chang A, Chang JH, Chon B, Confer ME, Demizu Y, Dendale R, Doyen J, Ermoian R, Gurtner K, Hill-kayser C, Iwata H, Kim J, Kwok Y, Laack NN, Lee C, Lim DH, Loredo L, Mangona VS, Mansur DB, Murakami M, Murayama S, Ogino T, Ondrová B, Parikh RR, Paulino AC, Perkins S, Ramakrishna NR, Richter R, Rombi B, Shibata S, Shimizu S, Timmermann B, Vern-gross T, Wang CJ, Weber DC, Wilkinson JB, Witt Nyström P, Yock TI, Kleinerman RA, Berrington de Gonzalez A. Patterns of proton therapy use in pediatric cancer management in 2016: An international survey. Radiotherapy and Oncology 2019;132:155-61. [DOI: 10.1016/j.radonc.2018.10.022] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
18 Hata M. Radiation therapy for elderly patients with uterine cervical cancer: feasibility of curative treatment. Int J Gynecol Cancer 2019;29:622-9. [PMID: 30630886 DOI: 10.1136/ijgc-2018-000077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]